Oophorectomy improves pituitary activin inhibitory function preventing lactotroph hyperplasia development

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Prolactinomas are the most common pituitary tumors, often treated with dopamine agonists.
• A significant subset of patients (25%) exhibit resistance to dopamine agonists, necessitating novel therapeutic strategies.
• Pituitary activins are known to inhibit lactotroph function, but their role in drug-resistant prolactinomas is not fully understood.

Purpose of the Study:

• To investigate the role of pituitary activins in preventing lactotroph hyperplasia.
• To explore the therapeutic potential of targeting activins for drug-resistant prolactinomas.

Main Methods:

• Utilized mouse models of lactotroph hyperplasia (transgenic and knockout mice).
• Performed oophorectomy at a young age (2 months) and assessed effects in adulthood.
• Evaluated pituitary activin expression, activin receptor expression in lactotrophs, and Pit-1 expression.

Main Results:

• Oophorectomy in mice led to recovery of pituitary activin expression and activin receptor expression in lactotrophs.
• This recovery was associated with restored activin biological activity and reduced Pit-1 expression.
• Oophorectomy prevented lactotroph hyperplasia development in these animal models.

Conclusions:

• The loss of gonadal inhibins following oophorectomy appears to restore the inhibitory action of pituitary activins on lactotroph function.
• These findings position pituitary activins as a promising therapeutic target for managing drug-resistant prolactinomas.